CO-DIAGNOSTICS DL-,001 Forum: Community User: tms33

Kommentare 12.275
A
Astraman25, 29.10.2025 13:35 Uhr
0

Hab das Gefühl das du schön.lana genommen wurdest

Ab ins Igno mit dir
T
ThmsK, 29.10.2025 13:31 Uhr
0
Und zurück zu 0,3€. Schöner Pump and Dump.
dynamic
dynamic, 29.10.2025 13:31 Uhr
0

Hier geht es nur noch runter!

💯
dynamic
dynamic, 29.10.2025 13:30 Uhr
1

Pumpt gut nach oben

Meintest wohl damit nach unten...🤭
A
Ansel, 29.10.2025 13:29 Uhr
1
Es ist echt ein Alptraum
Trading989
Trading989, 29.10.2025 13:28 Uhr
0

Lässt euch nicht abmaulen 😊

😃😃😃😃
AMK2020
AMK2020, 29.10.2025 13:26 Uhr
2

Zieh an du alte Sau

Hier geht es nur noch runter!
Trading989
Trading989, 29.10.2025 13:26 Uhr
0
Lässt euch nicht abmaulen 😊
AMK2020
AMK2020, 29.10.2025 13:25 Uhr
0

SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance. Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument. The decision by the Company to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability. Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.

Hab das Gefühl das du schön.lana genommen wurdest
Trading989
Trading989, 29.10.2025 13:25 Uhr
0
Zieh an du alte Sau
A
Astraman25, 29.10.2025 13:00 Uhr
0
The Company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new test's performance. A new submission also allows the Company to incorporate more recent Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will also help to create greater operational and manufacturing efficiencies, such as consolidating manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform. The Company's primary objective is to execute a robust development and commercialization plan for the Co-Dx PCR platform, including ongoing innovations to the PCR Pro instrument. The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others. *The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
A
Astraman25, 29.10.2025 12:59 Uhr
0
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance. Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument. The decision by the Company to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability. Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.
AMK2020
AMK2020, 29.10.2025 12:57 Uhr
0

Pumpt gut nach oben

Sag mal bist du mit dem Egon verwandt?
AMK2020
AMK2020, 29.10.2025 12:56 Uhr
0
Alle die auf lana stehen dürfen sich gleich freuen ☝🏻
Trading989
Trading989, 29.10.2025 12:50 Uhr
0
Pumpt gut nach oben
dynamic
dynamic, 29.10.2025 12:43 Uhr
0
0,428 €
Meistdiskutiert
Thema
1 NVIDIA Hauptdiskussion -4,51 %
2 Beyond Meat Hauptdiskussion +18,62 %
3 MICROSOFT Hauptdiskussion -5,75 %
4 PLUG POWER Hauptdiskussion -10,05 %
5 Critical Metals: Grönland - Tanbreez seltene Erden +9,97 %
6 RHEINMETALL Hauptdiskussion +1,28 %
7 AMAZON Hauptdiskussion +1,47 %
8 Novo Nordisk nach Split +5,06 %
9 DAX Hauptdiskussion +1,43 %
10 Critical Infrastructure Technologies Hauptdiskussion +0,25 %
Alle Diskussionen
Aktien
Thema
1 NVIDIA Hauptdiskussion -4,03 %
2 Beyond Meat Hauptdiskussion +16,18 %
3 MICROSOFT Hauptdiskussion -3,29 %
4 PLUG POWER Hauptdiskussion -10,35 %
5 Critical Metals: Grönland - Tanbreez seltene Erden +9,65 %
6 RHEINMETALL Hauptdiskussion +1,19 %
7 AMAZON Hauptdiskussion -1,38 %
8 Novo Nordisk nach Split +5,02 %
9 Critical Infrastructure Technologies Hauptdiskussion +0,25 %
10 ZALANDO Hauptdiskussion -0,86 %
Alle Diskussionen